Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Evidence may include medical records, testimonies, and documentation
Many plans exclude GLP-1s prescribed for weight loss while continuing to cover the same molecules prescribed for type 2 diabetes
Mar 19, 2026, 12:04 ET Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment * with Wegovy HD (~19% regardless of whether patients stayed on treatment ** ) in the STEP UP trial 1 In the STEP UP trial, about one in three trial participants taking Wegovy HD achieved 25% weight loss or higher 1 This approval for Wegovy further expands its already robust label inclusive of multiple formulations, including Wegovy pill, and indications not available with other GLP-1 weight loss medicines PLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy , Wegovy HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in adults with obesity in the STEP UP trial
Function in cardiac diseases Heart failure (HF) is characterized by metabolic abnormalities
Why Choose Why Choose Wegovy contains semaglutide , a GLP-1 receptor agonist that works by mimicking a natural hormone (glucagon-like peptide-1) in the body
